#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Breast angiosarcoma Chondrodystrophy Chronic graft versus host disease in skin Palmoplantar pustulosis Ovarian cancer Antiphospholipid antibodies Polycythaemia vera Infantile apnoea Autoimmune hepatitis Acquired ATTR amyloidosis Chronic inflammatory demyelinating polyradiculoneuropathy Follicular lymphoma stage II Marginal zone lymphoma recurrent Craniopharyngioma Stiff person syndrome More trials…

    Learn about Rare Diseases

    Kearns-Sayre syndrome – Life with Disease Nephroblastoma Atypical haemolytic uraemic syndrome – Life with Disease Indolent systemic mastocytosis Hepatic angiosarcoma – Treatment Medulloblastoma – Diagnostics Hairy cell leukaemia recurrent – Life with Disease IgA nephropathy – Basic Information Synovial sarcoma recurrent – Life with Disease Familial haemophagocytic lymphohistiocytosis – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    4-IODOPHENYLALANINE I-131 Iph5201 Epoetin Alfa Opevesostat Stro-002 GSK3862995B Codeine Phosphate Hemihydrate Farletuzumab Ecteribulin Bi 690517 Nicotinamide Citalopram Cefepime Fludrocortisone Golexanolone Valine Psilocybine Eribulin AGALSIDASE BETA Piperacillin Monohydrate Rp1 More therapies…

    Learn about Your Condition

    Lymphangiosarcoma Infectious pleural effusion Papilloma viral infection Cerebrovascular accident Clinically isolated syndrome Becker's muscular dystrophy Biotinidase deficiency Autoimmune haemolytic anaemia Perthes disease Crigler-Najjar syndrome Mucosal inflammation End stage renal disease B-cell lymphoma recurrent Rhinitis allergic Viral myocarditis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut De Cancerologie De Lorraine

Institut De Cancerologie De Lorraine

6 Avenue De Bourgogne, Cs 30519, Vandoeuvre Les Nancy, 54519, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Cyclophosphamide
    • Docetaxel
    Belgium France Greece Ireland Italy Poland +1

  • Study evaluating HER2DX-guided treatment in patients with early-stage HER2-positive breast cancer using trastuzumab, pertuzumab and combination chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • Carboplatin
    • Cyclophosphamide
    • Docetaxel
    France Germany Ireland Spain

  • Study of ivonescimab with chemotherapy combination for first and second-line treatment in patients with advanced or metastatic gastric and gastroesophageal cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Gastric cancer stage IV
    • Oesophageal carcinoma
    Investigated Drugs:
    • Calcium Levofolinate
    • Ivonescimab
    • Fluorouracil
    France

  • Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Mirvetuximab Soravtansine
    • Prednisolone Acetate
    Belgium France Poland Spain

  • Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Datopotamab Deruxtecan
    Austria Belgium Czechia Denmark France Germany +5

  • Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neuroendocrine tumour of the lung
    • Gastroenteropancreatic neuroendocrine tumour disease
    Investigated Drugs:
    • Dacarbazine
    • Topotecan
    • Atezolizumab
    France

  • Study of XL092 and belzutifan combination therapy in people with clear cell kidney cancer who had disease return during or after immunotherapy treatment

    Recruiting

    1 1 1
    Investigated Drugs:
    • Belzutifan
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    France Poland Spain

  • Study of zanidatamab in adult patients with HER2-positive solid tumors (endometrial, colorectal, head & neck, sarcoma) or HER2-mutant non-small cell lung cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • HER2 mutant non-small cell lung cancer
    • Sarcoma
    • Head and neck cancer
    Investigated Drugs:
    • Zanidatamab
    France

  • Study of Regorafenib and Maintenance Chemotherapy for Newly Diagnosed Ewing Sarcoma Patients with Metastatic Disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ewing’s sarcoma
    Investigated Drugs:
    • Vinorelbine
    • Cyclophosphamide
    Denmark France The Netherlands Norway Spain

  • Study of NBTXR3 and Cetuximab for Elderly Patients with Advanced Head and Neck Cancer Ineligible for Platinum Chemotherapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • HAFNIUM OXIDE
    • Cetuximab
    Austria Belgium Czechia France Germany Greece +4
Previous Page
1 2 3 4 5 … 18
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!